Convertible ROS Nanocatalyst/Eliminator for Enhancing Tumor Radio‐Immunotherapy and Relieving Radiation Enteritis
Advanced Science · 2025
DOI: 10.1002/advs.202503602 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Mengmeng Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shandong Cancer Hospital and Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 2501…. Hauptthemen laut MEDLINE: Enteritis, Reactive Oxygen Species, Immunotherapy, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Radiation‐induced damage to normal tissue seriously disrupts the execution of radiotherapy (RT) and therefore attenuates its efficacy. Exploring new strategies to enhance the efficacy and reduce toxicity of RT has great clinical importance. Here, a PD‐L1 affibody (Z PD‐L1 ) grafted Janus Ag/Ag 2 S nanoarchitectures is developed as “reactive oxygen species lever” to enhance radiocatalysis and relieve radiation enteritis. The nanoplatform can achieve abundant energy deposition in the form of high‐energy electrons within tumors upon X‐ray exposure. Subsequently, the transfer of electrons from Ag 2 S to Ag moiety enables effective electron–hole pair separation, which greatly improves the radiocatalysis efficiency in generating highly toxic hydroxyl radical (•OH). Due to the specific binding to tumor PD‐L1, Z PD‐L1 endows this nanoplatform with efficient tumor targeting and meanwhile reduces immune suppression of T cells by achieving PD‐1/PD‐L1 blockade, intensifying RT‐induced immunologic cell death. Notably, the presence of the Ag moiety allows the nanoplatform to act as an H 2 O 2 scavenger in intestinal tissues during metabolism, effectively relieving radiation enteritis. Moreover, systemic administration of the nanoplatform coupled with Mn‐DOTA can guide RT timing selection by magnetic resonance imaging. Overall, this nanoplatform can substantially improve RT effectiveness with reduced radiation enteritis, demonstrating considerable potential in tumor RT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Shandong Cancer Hospital and Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, China.
- Medical Science and Technology Innovation Center, Tumor Research and Therapy Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, China.
- Department of Chemical and Biomolecular Engineering, National University of Singapore, Singapore, 117585, Singapore.
ORCID-Profile: Xiao Sun
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong
- China Postdoctoral Science Foundation
- Youth Innovation Science and Technology Program of Shandong Provincial Universities
- Collaborative Academic Innovation Project of Shandong Cancer Hospital
- Natural Science Foundation of Shandong Province
Zitieren
APA
Zhang, M., Zhang, X., Wang, C., Mu, M., Ren, K., Ni, N., Yip, L. X., Guo, K., Hu, X., Teng, F., Leong, D. T., Fan, Q., & Sun, X. (2025). Convertible ROS Nanocatalyst/Eliminator for Enhancing Tumor Radio‐Immunotherapy and Relieving Radiation Enteritis. Advanced Science. https://doi.org/10.1002/advs.202503602
Vancouver
Zhang M, Zhang X, Wang C, Mu M, Ren K, Ni N, et al. Convertible ROS Nanocatalyst/Eliminator for Enhancing Tumor Radio‐Immunotherapy and Relieving Radiation Enteritis. Advanced Science. 2025. doi:10.1002/advs.202503602
BibTeX
@article{Zhang2025,
author = {Zhang, Mengmeng and Zhang, Xinyu and Wang, Chenyu and Mu, Mengyao and Ren, Ke and Ni, Nengyi and Yip, Li Xian and Guo, Kai and Hu, Xiaoyu and Teng, Feifei and Leong, David Tai and Fan, Qing and Sun, Xiao},
title = {Convertible ROS Nanocatalyst/Eliminator for Enhancing Tumor Radio‐Immunotherapy and Relieving Radiation Enteritis},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202503602}
}
EUVIMED